When was Numa Biosciences founded?

Numa Biosciences was founded in 2007 and raised its 1st funding round within a year of its incorporation.

Where is Numa Biosciences located?

Numa Biosciences is headquartered in Woodinville, United States. It is registered at Woodinville, Washington.

Who is the current CEO of Numa Biosciences?

Thomas Neumann of Numa Biosciences.

How many employees does Numa Biosciences have?

As of May 31, 2026, the latest employee count at Numa Biosciences is 9.

Is Numa Biosciences a funded company?

Numa Biosciences is a funded company, having raised a total of $10.7M across 19 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 2007.

When was the latest funding round of Numa Biosciences?

Numa Biosciences' latest funding was a $***** Grant (prize money) round on Aug 01, 2023, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $802M in funding in 2026 to date.

Where does Numa Biosciences rank among its competitors?

Numa Biosciences ranks 4th amongst 42 active competitors, of which 22 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Emulate, which secured $493K in Sep, 2025.

Who are the top competitors of Numa Biosciences?

Numa Biosciences' top competitors include Emulate, CN Bio and Hesperos. Among them, Emulate secured the most recent funding round in September, 2025.

Numa Biosciences - 2026 Company Profile, Team, Funding & Competitors

Numa Biosciences is an acquired company based in Woodinville (United States), founded in 2007. It operates as a Developer of platform for generating small segments of human tissues and organs in microfluidic chips. Numa Biosciences has raised $10.7M in funding. The company has 42 active competitors, including 22 funded and 1 that has exited. Its top competitors include companies like Emulate, CN Bio and Hesperos.

Company Details

Developer of platform for generating small segments of human tissues and organs in microfluidic chips. The company's ParVivoTM system is the pre-seeded chip platform that provides microphysiological environments for in vitro biomedical research and drug discovery.

Website: nortisbio.com
Social
Email ID: *****@nortisbio.com
Registered Address: Woodinville, Washington

Key Metrics

Founded Year

2007

Location

Woodinville, United States

Stage

Acquired

Total Funding

$10.7M in 19 rounds

Latest Funding Round

Grant (prize money), Aug 01, 2023, $*****

Investors

Vertical Venture Partners & 4 more

Ranked

4^th among 42 active competitors

Employee Count

9 as on May 31, 2026

Similar Companies

Emulate & 42 more

Exit Details

Acquired by Quris Ai (Oct 29, 2024)

View Numa Biosciences' full profile

Numa Biosciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Nortis Inc CIN: 680649212 , United States, Active	Dec 31, 1999	-	18 (As on Dec 31, 2023)	-

Numa Biosciences got acquired by Quris Ai on Oct 29, 2024.

Click here to take a look at Numa Biosciences's acquisition in detail

Numa Biosciences has raised a total funding of $10.7M over 19 rounds. Its first funding round was on Oct 2007. Its latest funding round was a Grant (prize money) round on Aug 01, 2023 for $*****. 1 investor participated in its latest round. Numa Biosciences has 5 institutional investors.

Here is the list of recent funding rounds of Numa Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 01, 2023	3208250	Grant (prize money)	7435915	1339287	2414003	6433339
Aug 19, 2022	6321746	Series A	2875370	3343005	8366166	3306583
Jun 04, 2021	8113580	Conventional Debt	1811888	4115735	2999860	9535727

Access funding benchmarks and valuations. Sign up today!

View details of Numa Biosciences's funding rounds and investors

Numa Biosciences' employee count trend

Numa Biosciences has 9 employees as of May 26. Here is Numa Biosciences's employee count trend over the years:

Employee count trend for Numa Biosciences

Uncover Numa Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Numa Biosciences include Emulate, CN Bio and Hesperos. Here is the list of Top 10 competitors of Numa Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Emulate 2013, Boston (United States), Series E	Developer of in vitro models for drug development	$204M	ND Capital, Cedars Sinai & 25 others	58/100
2nd	CN Bio 2009, Cambridge (United Kingdom), Series B	Develops organ-on-a-chip platforms for drug discovery	$71.8M	CITIC, Zray Management & 13 others	58/100
3rd	Hesperos 2015, Orlando (United States), Funding Raised	Developer of organ-on-a-chip solutions for preclinical testing	-	HHS, NCATS	53/100
4th	Numa Biosciences 2007, Woodinville (United States), Acquired	Developer of platform for generating small segments of human tissues and organs in microfluidic chips	$10.7M	Vertical Venture Partners, Corewell Health Ventures ... & 3 others	50/100
5th	Mimetas 2013, Leiden (Netherlands), Series B	Develops microfluidics-based organ-on-a-chip tissue models	$28.9M	Zeeuws Investerings Fonds, Oost NL & 13 others	45/100
6th	Obatala Sciences 2017, New Orleans (United States), Series A	Provider of research enabling products and services to research centers	$3.54M	Ochsner, Ochsner Lafayette General & 9 others	43/100
7th	Cellbox Labs 2020, Riga (Latvia), Seed	Provider of organ-on-chip platform for drug discovery and development	$1.01M	Buildit, European Innovation Council & 5 others	43/100
8th	Okomera 2020, Paris (France), Seed	Developer of a device for in vitro cancer testing using a microfluidic chip	$11.2M	Resonance, Polytechnique Ventures & 4 others	42/100
9th	Mepsgen 2019, Seoul (South Korea), Series C	Developer of human organ model chips for pharmaceutical development	$29.3M	E&Investment, Korean Development Bank & 6 others	40/100
10th	NETRI 2018, Lyon (France), Series A	Developer of microfluidic devices for industrial applications	$14M	Bpifrance, Netangels & 4 others	40/100